PT - JOURNAL ARTICLE AU - Luccarelli, James AU - Clauss, Jacqueline A. AU - York, Tasia AU - Baldwin, Isaac AU - Vandekar, Simon AU - McGonigle, Trey AU - Fricchione, Gregory AU - Fuchs, Catherine AU - Smith, Joshua R. TI - Exploring the Trajectory of Catatonia in Neurodiverse and Neurotypical Pediatric Hospitalizations: A Multicenter Longitudinal Analysis AID - 10.1101/2024.06.06.24308554 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.06.24308554 4099 - http://medrxiv.org/content/early/2024/06/07/2024.06.06.24308554.short 4100 - http://medrxiv.org/content/early/2024/06/07/2024.06.06.24308554.full AB - Objective Catatonia is a neuropsychiatric disorder that occurs in pediatric patients with a range of associated medical, psychiatric, and neurodevelopmental disorders (NDDs). This study describes hospital care of pediatric catatonia patients and compares treatments for neurotypical patients and those with NDDs.Methods Retrospective cohort study from 1/1/2018 to 6/1/2023 of two academic medical centers of patients aged 18 and younger with catatonia. Patients were retrospectively assessed using the clinical global impressions-improvement (CGI-I) by two independent reviewers.Results One hundred sixty-five patients were hospitalized for catatonia, of whom 50.3% had an NDD. Median age was 15. One hundred sixty-four patients were treated with a benzodiazepine, with a median maximum 24-hour dose of 6 mg lorazepam-equivalents, which did not differ for patients with and without NDDs. Electroconvulsive therapy (ECT) was utilized in 14.5% of patients. Median length of medical hospitalization was 5 days and hospitalizations were longer in neurotypical patients than in patients with NDDs. In an ordinal regression model, the probability of observing at least “much improvement” (CGI < 3) was 88.3% (95% CI: 82.4% to 92.3%), with NDD diagnosis associated with a lower odds of clinical response.Conclusions The probability of patients achieving a CGI-I score indicating at least “much improvement” was 88.3%. Administered benzodiazepine dose and ECT treatment were similar for all patients, but neurotypical patients had longer hospitalizations than those with NDDs and had a higher odds of a more favorable clinical response. Research under controlled conditions is needed to optimize and endure equitable catatonia treatment in youth.Competing Interest StatementJL receives funding from Harvard Medical School Dupont Warren Fellowship and Livingston Awards, the Rappaport Foundation, and the Foundation for Prader-Willi Research. He has received equity and consulting fees from Revival Therapeutics, Inc. JAC receives funding from the Harvard Medical School Dupont-Warren Fellowship, the Chen Institute Mass General Neuroscience Transformative Scholar Award, and the Louis V. Gerstner Award. GF has received equity from Revival Therapeutics, IP royalties from Adya Health and is on the scientific advisory board of Being Health. JRS receives funding from Roche, Axial Therapeutics, and the National Institute of Child and Human Development. All other authors report no disclosures.Funding StatementThis work was supported by the National Institute of Mental Health (T32MH112485; JL and JAC) and National Institute of Child and Human Development (1P50HD103537; JRS). The sponsor had no role in study design, writing of the report, or data collection, analysis, or interpretation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRBs of Mass General Brigham and Vanderbilt University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data are not publicly available due to privacy restrictions from secondary use of individually identifying healthcare data; however, reasonable requests for supporting data can be directed to the corresponding author.